Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IDEXX LABORATORIES INC /DEIDXX · Entity 3057 | Executive Vice President | March 06, 2024 | March 07, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IDEXX LABORATORIES INC /DE
Report date March 06, 2024 · Filed March 07, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,711.2345 |
Ending reported balance
After 2024-03-06 transaction · row 7
7 source rows · reconciled sequenceRow 1 · 2024-03-06 · Exercise / conversion · Acquired 755 · Balance 11,466.2345 Row 2 · 2024-03-06 · Exercise / conversion · Acquired 483 · Balance 11,949.2345 Row 3 · 2024-03-06 · Exercise / conversion · Acquired 2,226 · Balance 14,175.2345 Row 4 · 2024-03-06 · Exercise / conversion · Acquired 4,640 · Balance 18,815.2345 Row 5 · 2024-03-06 · Sale · Disposed 4,134 · Balance 14,681.2345 F1: Represents the weighted average price of the shares sold ranging from a low of $557.33 to a high of $558.32 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Row 6 · 2024-03-06 · Sale · Disposed 3,290 · Balance 11,391.2345 F2: Represents the weighted average price of the shares sold ranging from a low of $558.45 to a high of $559.29 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Row 7 · 2024-03-06 · Sale · Disposed 680 · Balance 10,711.2345 F3: Represents the weighted average price of the shares sold ranging from a low of $559.51 to a high of $559.74 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. |
| Non-Qualified Stock Option (right-to-buy)SEC Table II · derivative / convertible security · Conversion / exercise price $206.94 · Expires 2029-02-13 | Direct | 0 |
Reported balance
After 2024-03-06 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2024-03-06 · Exercise / conversion · Disposed 755 · Balance 0 F4: Grant of option to buy 5,711 shares of Issuer common stock that vest in five annual installments beginning February 14, 2020. |
| Non-Qualified Stock Option (right-to-buy)SEC Table II · derivative / convertible security · Conversion / exercise price $288.78 · Expires 2030-02-13 | Direct | 0 |
Reported balance
After 2024-03-06 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2024-03-06 · Exercise / conversion · Disposed 2,226 · Balance 0 F6: Grant of option to buy 8,906 shares of Issuer common stock that vest in four annual installments beginning February 14, 2021. |
| Non-Qualified Stock Option (right-to-buy)SEC Table II · derivative / convertible security · Conversion / exercise price $544.08 · Expires 2031-02-13 | Direct | 1,363 |
Reported balance
After 2024-03-06 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2024-03-06 · Exercise / conversion · Disposed 4,640 · Balance 1,363 F7: Grant of option to buy 6,003 shares of Issuer common stock that vest in four annual installments beginning February 14, 2022. |
| Incentive Stock Option (right-to-buy)SEC Table II · derivative / convertible security · Conversion / exercise price $206.94 · Expires 2029-02-13 | Direct | 0 |
Reported balance
After 2024-03-06 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2024-03-06 · Exercise / conversion · Disposed 483 · Balance 0 F5: Grant of option to buy shares of Issuer common stock that vested in one installment on February 14, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the weighted average price of the shares sold ranging from a low of $557.33 to a high of $558.32 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
F2: Represents the weighted average price of the shares sold ranging from a low of $558.45 to a high of $559.29 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
F3: Represents the weighted average price of the shares sold ranging from a low of $559.51 to a high of $559.74 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
F4: Grant of option to buy 5,711 shares of Issuer common stock that vest in five annual installments beginning February 14, 2020.
F5: Grant of option to buy shares of Issuer common stock that vested in one installment on February 14, 2024.
F6: Grant of option to buy 8,906 shares of Issuer common stock that vest in four annual installments beginning February 14, 2021.
F7: Grant of option to buy 6,003 shares of Issuer common stock that vest in four annual installments beginning February 14, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 06, 2024 Filed Mar 7, 2024 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 4,640 | $0.00 Strike: $544.08 | $0.00 |
DisclosureSEC source: 0000874716-24-000065 · wk-form4_1709848825.xml · derivative · entry 11 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,363 Underlying: Common Stock · 4,640 shares Expires 2031-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Grant of option to buy 6,003 shares of Issuer common stock that vest in four annual installments beginning February 14, 2022. Read SEC document |
| March 06, 2024 Filed Mar 7, 2024 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 2,226 | $0.00 Strike: $288.78 | $0.00 |
DisclosureSEC source: 0000874716-24-000065 · wk-form4_1709848825.xml · derivative · entry 10 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,226 shares Expires 2030-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Grant of option to buy 8,906 shares of Issuer common stock that vest in four annual installments beginning February 14, 2021. Read SEC document |
| March 06, 2024 Filed Mar 7, 2024 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionIncentive Stock Option (right-to-buy) · Derivative | 483 | $0.00 Strike: $206.94 | $0.00 |
DisclosureSEC source: 0000874716-24-000065 · wk-form4_1709848825.xml · derivative · entry 9 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 483 shares Expires 2029-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that vested in one installment on February 14, 2024. Read SEC document |
| March 06, 2024 Filed Mar 7, 2024 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 755 | $0.00 Strike: $206.94 | $0.00 |
DisclosureSEC source: 0000874716-24-000065 · wk-form4_1709848825.xml · derivative · entry 8 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 755 shares Expires 2029-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Grant of option to buy 5,711 shares of Issuer common stock that vest in five annual installments beginning February 14, 2020. Read SEC document |
| March 06, 2024 Filed Mar 7, 2024 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 680 | $559.33 | $380,345.62 |
DisclosureSEC source: 0000874716-24-000065 · wk-form4_1709848825.xml · nonDerivative · entry 7 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,711.2345 F3 · price: Represents the weighted average price of the shares sold ranging from a low of $559.51 to a high of $559.74 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| March 06, 2024 Filed Mar 7, 2024 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 3,290 | $558.88 | $1,838,722.44 |
DisclosureSEC source: 0000874716-24-000065 · wk-form4_1709848825.xml · nonDerivative · entry 6 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,391.2345 F2 · price: Represents the weighted average price of the shares sold ranging from a low of $558.45 to a high of $559.29 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| March 06, 2024 Filed Mar 7, 2024 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 4,134 | $557.94 | $2,306,528.09 |
DisclosureSEC source: 0000874716-24-000065 · wk-form4_1709848825.xml · nonDerivative · entry 5 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,681.2345 F1 · price: Represents the weighted average price of the shares sold ranging from a low of $557.33 to a high of $558.32 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| March 06, 2024 Filed Mar 7, 2024 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 4,640 | $544.08 | $2,524,531.20 |
DisclosureSEC source: 0000874716-24-000065 · wk-form4_1709848825.xml · nonDerivative · entry 4 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,815.2345 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 06, 2024 Filed Mar 7, 2024 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 2,226 | $288.78 | $642,824.28 |
DisclosureSEC source: 0000874716-24-000065 · wk-form4_1709848825.xml · nonDerivative · entry 3 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,175.2345 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 06, 2024 Filed Mar 7, 2024 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 483 | $206.94 | $99,952.02 |
DisclosureSEC source: 0000874716-24-000065 · wk-form4_1709848825.xml · nonDerivative · entry 2 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,949.2345 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 06, 2024 Filed Mar 7, 2024 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 755 | $206.94 | $156,239.70 |
DisclosureSEC source: 0000874716-24-000065 · wk-form4_1709848825.xml · nonDerivative · entry 1 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,466.2345 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:57 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 220 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000041 · wk-form4_1708124235.xml · derivative · entry 11 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 660 Underlying: Common Stock · 220 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2024. F6 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2024. F6 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2024. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:57 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 204 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000041 · wk-form4_1708124235.xml · derivative · entry 10 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 408 Underlying: Common Stock · 204 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2023. F5 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2023. F5 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2023. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:57 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 161 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000041 · wk-form4_1708124235.xml · derivative · entry 9 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 160 Underlying: Common Stock · 161 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2022. F4 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2022. F4 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2022. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:57 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 216 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000041 · wk-form4_1708124235.xml · derivative · entry 8 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 216 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in four annual installments, beginning February 14, 2021. F3 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in four annual installments, beginning February 14, 2021. F3 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in four annual installments, beginning February 14, 2021. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:57 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 126 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000041 · wk-form4_1708124235.xml · derivative · entry 7 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 126 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in five annual installments, beginning February 14, 2020. F2 · derivative.exercise_date: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in five annual installments, beginning February 14, 2020. F2 · derivative.expiration_date: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in five annual installments, beginning February 14, 2020. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:57 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Tax withholdingCommon Stock | 279 | $560.56 | $156,396.24 |
DisclosureSEC source: 0000874716-24-000041 · wk-form4_1708124235.xml · nonDerivative · entry 6 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,711.2345 Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:57 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 220 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000041 · wk-form4_1708124235.xml · nonDerivative · entry 5 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,990.2345 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:57 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 204 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000041 · wk-form4_1708124235.xml · nonDerivative · entry 4 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,770.2345 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:57 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 161 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000041 · wk-form4_1708124235.xml · nonDerivative · entry 3 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,566.2345 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:57 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 216 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000041 · wk-form4_1708124235.xml · nonDerivative · entry 2 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,405.2345 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 22:57 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 126 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-24-000041 · wk-form4_1708124235.xml · nonDerivative · entry 1 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,189.2345 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 13.2470 shares purchased under the Issuer Employee Stock Purchase Plan on December 29, 2023. Read SEC document |
| December 07, 2023 Filed Dec 8, 2023 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 6,680 | $0.00 Strike: $288.78 | $0.00 |
DisclosureSEC source: 0000874716-23-000145 · wk-form4_1702072812.xml · derivative · entry 8 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,226 Underlying: Common Stock · 6,680 shares Expires 2030-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Grant of option to buy 8,906 shares of Issuer common stock that vest in four annual installments beginning February 14, 2021. Read SEC document |
| December 07, 2023 Filed Dec 8, 2023 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 4,956 | $0.00 Strike: $206.94 | $0.00 |
DisclosureSEC source: 0000874716-23-000145 · wk-form4_1702072812.xml · derivative · entry 7 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 755 Underlying: Common Stock · 4,956 shares Expires 2029-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Grant of option to buy 5,711 shares of Issuer common stock that vest in five annual installments beginning February 14, 2020. Read SEC document |
| December 07, 2023 Filed Dec 8, 2023 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 3,940 | $523.56 | $2,062,811.82 |
DisclosureSEC source: 0000874716-23-000145 · wk-form4_1702072812.xml · nonDerivative · entry 6 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,049.9875 F5 · price: Represents the weighted average price of the shares sold ranging from a low of $523.05 to a high of $523.885 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| December 07, 2023 Filed Dec 8, 2023 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 1,202 | $522.31 | $627,815.90 |
DisclosureSEC source: 0000874716-23-000145 · wk-form4_1702072812.xml · nonDerivative · entry 5 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,989.9875 F4 · price: Represents the weighted average price of the shares sold ranging from a low of $521.99 to a high of $522.935 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| December 07, 2023 Filed Dec 8, 2023 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 3,378 | $521.00 | $1,759,953.54 |
DisclosureSEC source: 0000874716-23-000145 · wk-form4_1702072812.xml · nonDerivative · entry 4 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,191.9875 F3 · price: Represents the weighted average price of the shares sold ranging from a low of $520.74 to a high of $521.235 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| December 07, 2023 Filed Dec 8, 2023 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 3,116 | $520.19 | $1,620,918.90 |
DisclosureSEC source: 0000874716-23-000145 · wk-form4_1702072812.xml · nonDerivative · entry 3 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,569.9875 F2 · price: Represents the weighted average price of the shares sold ranging from a low of $519.73 to a high of $520.73 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| December 07, 2023 Filed Dec 8, 2023 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 6,680 | $288.78 | $1,929,050.40 |
DisclosureSEC source: 0000874716-23-000145 · wk-form4_1702072812.xml · nonDerivative · entry 2 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,685.9875 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 07, 2023 Filed Dec 8, 2023 22:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 4,956 | $206.94 | $1,025,594.64 |
DisclosureSEC source: 0000874716-23-000145 · wk-form4_1702072812.xml · nonDerivative · entry 1 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,005.9875 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 12 shares purchased under the Issuer's Employee Stock Purchase Plan on September 29, 2023. Read SEC document |
| August 29, 2023 Filed Aug 31, 2023 21:17 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 5,865 | $0.00 Strike: $178.26 | $0.00 |
DisclosureSEC source: 0000874716-23-000113 · wk-form4_1693516123.xml · derivative · entry 16 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,865 shares Expires 2028-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_date: Grant of option to buy 5,865 shares of Issuer common stock that vested in five annual installments beginning February 14, 2019. Read SEC document |
| August 29, 2023 Filed Aug 31, 2023 21:17 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionIncentive Stock Option (right-to-buy) · Derivative | 560 | $0.00 Strike: $178.26 | $0.00 |
DisclosureSEC source: 0000874716-23-000113 · wk-form4_1693516123.xml · derivative · entry 15 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 560 shares Expires 2028-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: Grant of option to buy 560 shares of Issuer common stock that vested in one installment on February 14, 2023. Read SEC document |
| August 29, 2023 Filed Aug 31, 2023 21:17 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 7,151 | $0.00 Strike: $141.60 | $0.00 |
DisclosureSEC source: 0000874716-23-000113 · wk-form4_1693516123.xml · derivative · entry 14 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,151 shares Expires 2027-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: Grant of option to buy 7,151 shares of Issuer common stock that vested in five annual installments beginning February 14, 2018. Read SEC document |
| August 29, 2023 Filed Aug 31, 2023 21:17 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionIncentive Stock Option (right-to-buy) · Derivative | 706 | $0.00 Strike: $141.60 | $0.00 |
DisclosureSEC source: 0000874716-23-000113 · wk-form4_1693516123.xml · derivative · entry 13 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 706 shares Expires 2027-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: Grant of option to buy 706 shares of Issuer common stock that vested in one installment on February 14, 2022. Read SEC document |
| August 29, 2023 Filed Aug 31, 2023 21:17 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 2,627 | $0.00 Strike: $68.75 | $0.00 |
DisclosureSEC source: 0000874716-23-000113 · wk-form4_1693516123.xml · derivative · entry 12 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,627 shares Expires 2026-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: Grant of option to buy 12,627 shares of Issuer common stock that vested in five annual installments beginning February 14, 2017. Read SEC document |
| August 29, 2023 Filed Aug 31, 2023 21:17 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 2,887 | $511.22 | $1,475,902.82 |
DisclosureSEC source: 0000874716-23-000113 · wk-form4_1693516123.xml · nonDerivative · entry 11 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,037.9875 F7 · price: Represents the weighted average price of the shares sold ranging from a low of $510.96 to a high of $511.94 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| August 29, 2023 Filed Aug 31, 2023 21:17 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 7,473 | $511.03 | $3,818,916.73 |
DisclosureSEC source: 0000874716-23-000113 · wk-form4_1693516123.xml · nonDerivative · entry 10 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,924.9875 F6 · price: Represents the weighted average price of the shares sold ranging from a low of $510.73 to a high of $511.67 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| August 29, 2023 Filed Aug 31, 2023 21:17 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 3,318 | $510.47 | $1,693,727.52 |
DisclosureSEC source: 0000874716-23-000113 · wk-form4_1693516123.xml · nonDerivative · entry 9 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,397.9875 F5 · price: Represents the weighted average price of the shares sold ranging from a low of $509.93 to a high of $510.90 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| August 29, 2023 Filed Aug 31, 2023 21:17 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 6,186 | $510.38 | $3,157,195.83 |
DisclosureSEC source: 0000874716-23-000113 · wk-form4_1693516123.xml · nonDerivative · entry 8 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,715.9875 F4 · price: Represents the weighted average price of the shares sold ranging from a low of $509.69 to a high of $510.68 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| August 29, 2023 Filed Aug 31, 2023 21:17 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 2,545 | $509.32 | $1,296,221.18 |
DisclosureSEC source: 0000874716-23-000113 · wk-form4_1693516123.xml · nonDerivative · entry 7 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,901.9875 F3 · price: Represents the weighted average price of the shares sold ranging from a low of $508.63 to a high of $509.63 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| August 29, 2023 Filed Aug 31, 2023 21:17 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 500 | $508.96 | $254,482.10 |
DisclosureSEC source: 0000874716-23-000113 · wk-form4_1693516123.xml · nonDerivative · entry 6 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,446.9875 F2 · price: Represents the weighted average price of the shares sold ranging from a low of $508.76 to a high of $509.42 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| August 29, 2023 Filed Aug 31, 2023 21:17 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 5,865 | $178.26 | $1,045,494.90 |
DisclosureSEC source: 0000874716-23-000113 · wk-form4_1693516123.xml · nonDerivative · entry 5 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,946.9875 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 29, 2023 Filed Aug 31, 2023 21:17 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 560 | $178.26 | $99,825.60 |
DisclosureSEC source: 0000874716-23-000113 · wk-form4_1693516123.xml · nonDerivative · entry 4 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,081.9875 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 29, 2023 Filed Aug 31, 2023 21:17 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 7,151 | $141.60 | $1,012,581.60 |
DisclosureSEC source: 0000874716-23-000113 · wk-form4_1693516123.xml · nonDerivative · entry 3 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,521.9875 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 29, 2023 Filed Aug 31, 2023 21:17 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 706 | $141.60 | $99,969.60 |
DisclosureSEC source: 0000874716-23-000113 · wk-form4_1693516123.xml · nonDerivative · entry 2 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,370.9875 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 29, 2023 Filed Aug 31, 2023 21:17 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 2,627 | $68.75 | $180,606.25 |
DisclosureSEC source: 0000874716-23-000113 · wk-form4_1693516123.xml · nonDerivative · entry 1 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,664.9875 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes a total of 26.7030 shares purchased under the Issuer's Employee Stock Purchase Plan on March 31, 2023 and June 30, 2023. Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 23:54 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 204 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-23-003221 · doc1.xml · derivative · entry 11 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,155 Underlying: Common Stock · 204 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2023. F6 · price: Not applicable. F5 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2023. F5 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2023. Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 23:54 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 161 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-23-003221 · doc1.xml · derivative · entry 10 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,359 Underlying: Common Stock · 161 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2022. F6 · price: Not applicable. F4 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2022. F4 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2022. Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 23:54 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 216 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-23-003221 · doc1.xml · derivative · entry 9 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,520 Underlying: Common Stock · 216 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2021. F6 · price: Not applicable. F3 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2021. F3 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in four annual installments, beginning February 14, 2021. Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 23:54 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 127 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-23-003221 · doc1.xml · derivative · entry 8 POLEWACZYK JAMES F · CIK 0001389046 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,736 Underlying: Common Stock · 127 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2020. F6 · price: Not applicable. F2 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2020. F2 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock. This RSU grant vests in five annual installments, beginning February 14, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.